Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. reports developments tied to its clinical-stage biotherapeutics platform for oral delivery of biologics and drugs. The company’s RaniPill® capsule technology is designed to deliver drug substances such as antibodies, proteins, peptides and oligonucleotides as an alternative to subcutaneous injection or intravenous infusion.
Recurring RANI news includes clinical and preclinical updates for RaniPill-based programs, including RT-114, a GLP-1/GLP-2 dual agonist program for obesity, and oral semaglutide work. Company updates also cover financial results, collaboration and license activity, private placement financing, manufacturing and supply-chain capabilities, pipeline prioritization, investor conference participation, and leadership or advisory appointments supporting platform and clinical strategy.
Rani Therapeutics announced a partnership with ProGen to develop RT-114, an oral obesity treatment using RaniPill® capsules and ProGen's dual agonist, PG-102. The collaboration features a 50/50 cost and revenue share, with Rani leading development in the US, Europe, Canada, and Australia, while ProGen heads efforts elsewhere. The RT-114 program aims to offer a weekly oral dose, potentially improving patient adherence and therapeutic effects. Previous clinical studies of both the RaniPill® platform and PG-102 have shown promising results in bioavailability and safety profiles.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, announced participation in two investor conferences in May 2024. The H.C. Wainwright 2nd Annual BioConnect Investor Conference will be held on May 20th at Nasdaq Headquarters, New York City, featuring a fireside chat and 1x1 investor meetings with CEO Talat Imran. The UBS Spring Biotech Conference will take place on May 21st at UBS, New York City, consisting of 1x1 investor meetings. Live webcast for the H.C. Wainright Conference will be available on Rani's website.
Rani Therapeutics, a clinical-stage biotherapeutics company, will present clinical and preclinical data on their oral delivery platform, the RaniPill® capsule, at Digestive Disease Week 2024. The data will focus on the oral delivery of an Ustekinumab biosimilar, showcasing high bioavailability in healthy human participants and canines. The presentations will take place virtually and in-person on May 18-21, 2024, in Washington, DC.
Rani Therapeutics reported positive topline results from a Phase 1 study for RT-111, an oral anti-Interleukin 12/23 antibody, and plans to initiate a Phase 2 clinical trial for RT-102 for osteoporosis treatment in 2024. The company's RaniPill HC is set for potential Phase 1 trials later in 2024. Financially, Rani Therapeutics had $39.6 million in cash, cash equivalents, and marketable securities as of March 31, 2024, with a decrease in research and development expenses compared to the previous year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.